Skip to main content
Fig. 4 | BMC Ophthalmology

Fig. 4

From: Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW

Fig. 4

Proportion of patients with a BCVA ≥70 letters by IVT-AFL regimen. Observed analysis. Regular treatment interval cohort: n = 102 (month 0); n = 102 (month 12); n = 70 (month 24). Irregular treatment interval cohort with initial doses: n = 268 (month 0); n = 268 (month 12); n = 142 (month 24). Irregular treatment interval cohort without initial doses: n = 60 (month 0); n = 60 (month 12); n = 40 (month 24). BCVA best corrected visual acuity, IVT-AFL intravitreal aflibercept

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us